FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®

Update Supports Broader Access to IMDELLTRA in Community Settings for People Living with Extensive-Stage Small Cell Lung Cancer THOUSAND OAKS, Calif., Sept. 14, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved an update to the — Company newsroom — sourced from Amgen. Matter furnished by the company. Not a Notice Nearby paid placement. This page reprints a substantial excerpt from the official release. Read the original for the full text. Read the original: https://investors.amgen.com/news-releases/news-release-details/fda-approves-reduced-monitoring-time-first-two-doses-imdelltrar